Video

Will Biosimilars Impact the Cost of Specialty Drugs?

Author(s):

Davy James, Managing Editor

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.

Related Videos
Pharmacist helping a patient with medication -- Image credit: Clayton D/peopleimages.com | stock.adobe.com
Related Content
NCCN 2025: Advancing Breast Cancer Risk Assessment and Prevention Strategies
April 1st 2025

NCCN 2025: Advancing Breast Cancer Risk Assessment and Prevention Strategies

Luke Halpern, Assistant Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Schizophrenia
April 1st 2025

Use of Long-Acting Injectable Antipsychotic Medications in Schizophrenia Treatment

Angie Oster, PharmD Cara Colodonato, PharmD
Pharmacy focus podcast
March 28th 2025

From Screening to Survival: The Pharmacist’s Role in Colorectal Cancer

Alexandra Gerlach, Associate Editor
Exploring the Tumor Microenvironment Interactions Between Cancer Cells, TCells, and Nanoparticles in Cancer Therapy and Immunology
March 31st 2025

NCCN 2025: Managing Immune Checkpoint Inhibitor-Related Toxicities in Cancer Care

Luke Halpern, Assistant Editor
Herpes Zoster as an Early Indicator of HIV: Clinical Insights
March 31st 2025

Herpes Zoster as an Early Indicator of HIV: Clinical Insights

Emilia Welch, PharmD, MBA